SCHEMBL3774972

SCHEMBL3774972

Cc1n[nH]c2ccnc(Nc3ccc(C(=O)N(C)C)cc3)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 1/20 0.46
FLT3 P36888 1/20 0.44
CYP1A2 P05177 7/20 0.43
CYP3A4 P08684 7/20 0.43
USP2 O75604 5/20 0.43
CYP2C19 P33261 4/20 0.43
AURKA O14965 1/20 0.42
CDK2 P24941 1/20 0.42
KCNH2 Q12809 1/20 0.42
ALDH1A1 P00352 4/20 0.42
CLK4 Q9HAZ1 4/20 0.42
TSHR P16473 3/20 0.42
LRRK2 Q5S007 3/20 0.41
CSNK2A1 P68400 1/20 0.41
HSD17B10 Q99714 2/20 0.41
ALOX15 P16050 1/20 0.41
LCK P06239 1/20 0.40
JAK3 P52333 1/20 0.40
LMNA P02545 4/20 0.40
CYP2D6 P10635 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768951 0.88 HTT (0.45) FYNFLT3CYP1A2CYP3A4ALDH1A1
SCHEMBL3766435 0.85 ROCK1 (0.44) FLT3AURKACDK2KCNH2CLK4
SCHEMBL3764198 0.84 HPGD (0.48) ALDH1A1LCKJAK3LMNAMAPK1
SCHEMBL3780712 0.81 MAPK8 (0.47) FYNAURKAALDH1A1LRRK2JAK3
SCHEMBL3775329 0.81 LRRK2 (0.61) LRRK2MAPK1MAPT
SCHEMBL3774496 0.80 GRM5 (0.47) FLT3LRRK2MAPK10MEN1KMT2A
SCHEMBL3775370 0.78 LRRK2 (0.63) CYP1A2CYP3A4CYP2C19CDK2LRRK2
SCHEMBL3763899 0.78 GRM4 (0.51) CDK2LRRK2LMNAMAPK10MAPK1
SCHEMBL3771247 0.78 LRRK2 (0.43) LRRK2MAPT
SCHEMBL3769478 0.78 BRAF (0.46) AURKAALDH1A1KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
EP-2408772-B1 COMPOUNDS MEDICAL RES COUNCIL TECHNOLOGY (GB) 2015-07-01 EP disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320870-A1 COMPOUNDS CBR3, CNR1, HCAR3 FYN 1103/4885FLT3 430/4885CYP1A2 613/4885
US-20100317646-A1 COMPOUNDS CBR3, CNR1, HCAR3 FYN 1138/4885FLT3 418/4885CYP1A2 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.